We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.87B
1-Year Est. Return 205.24%
This Fund
S&P 500
This Quarter Est. Return
-2.69%
1 Year Est. Return
+205.24%
3 Year Est. Return
+440.18%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.09B
AUM Growth
+$407M
Cap. Flow
+$944M
Cap. Flow %
30.56%
Top 10 Hldgs %
53.08%
Holding
79
New
16
Increased
25
Reduced
8
Closed
10

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$94.7M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$86.1M
3
PTGX icon
Protagonist Therapeutics
PTGX
+$83.8M
4
GERN icon
Geron
GERN
+$83.2M
5
TARS icon
Tarsus Pharmaceuticals
TARS
+$73.4M

Top Sells

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$125M
2
HRMY icon
Harmony Biosciences
HRMY
+$49.9M
3
NMRA icon
Neumora Therapeutics
NMRA
+$42.4M
4
GH icon
Guardant Health
GH
+$42.1M
5
GMAB icon
Genmab
GMAB
+$41.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RAPT
51
DELISTED
RAPT Therapeutics
RAPT
$7.33M 0.24%
751,423
– –
PLRX icon
52
Pliant Therapeutics
PLRX
$70M
$7.29M 0.24%
5,399,681
-572,576
-10% -$3.48M
AVTX icon
53
Avalo Therapeutics
AVTX
$878M
$6.89M 0.22%
859,876
-7,124
-0.8% -$54K
BCYC
54
Bicycle Therapeutics
BCYC
$256M
$6.51M 0.21%
767,016
-509,065
-40% -$6M
BEAM icon
55
Beam Therapeutics
BEAM
$2.39B
$6.17M 0.2%
+315,765
New +$8.27M
IVVD icon
56
Invivyd
IVVD
$240M
$5.88M 0.19%
9,722,254
-967,349
-9% -$868K
XNCR icon
57
Xencor
XNCR
$1.78B
$5.85M 0.19%
549,439
+49,439
+10% +$817K
RGLS
58
DELISTED
Regulus Therapeutics
RGLS
$5.71M 0.18%
3,262,564
– –
INO icon
59
Inovio Pharmaceuticals
INO
$117M
$5.08M 0.16%
3,119,162
– –
RAPP
60
Rapport Therapeutics
RAPP
$2.03B
$4.59M 0.15%
+457,556
New +$5.94M
CNTX icon
61
Context Therapeutics
CNTX
$33.8M
$4.54M 0.15%
7,419,355
– –
ZURA icon
62
Zura Bio
ZURA
$462M
$4.24M 0.14%
3,283,783
– –
ALGS icon
63
Aligos Therapeutics
ALGS
$31M
$3.66M 0.12%
444,110
+200,000
+82% +$4.38M
SYRE icon
64
Spyre Therapeutics
SYRE
$8.09B
$3.53M 0.11%
219,015
– –
IMA
65
ImageneBio Inc
IMA
$57.8M
$3.22M 0.1%
+209,626
New +$3.62M
OKUR
66
OnKure Therapeutics
OKUR
$117M
$2.25M 0.07%
523,989
– –
ALLK
67
DELISTED
Allakos
ALLK
$1.65M 0.05%
7,232,701
+1,528,419
+27% +$690K
NGNE icon
68
Neurogene
NGNE
$682M
$1.37M 0.04%
+116,660
New +$2.03M
CLYM
69
Climb Bio
CLYM
$821M
$1.27M 0.04%
1,040,115
– –
CNTA
70
DELISTED
Centessa Pharmaceuticals
CNTA
– –
-1,350,000
Closed -$22.6M
FDMT icon
71
4D Molecular Therapeutics
FDMT
$782M
– –
-609,900
Closed -$3.4M
GMAB icon
72
Genmab
GMAB
$21.3B
– –
-2,000,000
Closed -$41.7M
HRMY icon
73
Harmony Biosciences
HRMY
$2.5B
– –
-1,450,000
Closed -$49.9M
NKTR icon
74
Nektar Therapeutics
NKTR
$2.28B
– –
-131,733
Closed -$1.84M
NMRA icon
75
CALL
Neumora Therapeutics
NMRA
$150M
– –
-1,189,800
Closed -$12.6M
1 2
3
4

Similar funds

PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
EWM
Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return
NP
NorthRock Partners Minneapolis, Minnesota $6.89B AUM 19.83% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $6.92B AUM 24.7% 1-Year Est. Return
RCWMU
Rothschild & Co Wealth Management (UK) London, United Kingdom $6.93B AUM 1.4% 1-Year Est. Return
CA
Cambridge Associates Boston, Massachusetts $6.93B AUM 17.96% 1-Year Est. Return
LIP
Liontrust Investment Partners London, United Kingdom $6.8B AUM 23.31% 1-Year Est. Return
CI
Cincinnati Insurance Fairfield, Ohio $6.94B AUM 20.24% 1-Year Est. Return

Deep Track Capital's Q1 2025 Portfolio in Review

As of Q1 2025, Deep Track Capital held 79 positions worth $3.09B, up 15% from $2.68B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Deep Track Capital deployed $944M of net new capital in Q1 2025, opening 16 new positions and adding to 25 existing holdings. Its largest new stake was Sarepta Therapeutics: 899,731 shares worth $57.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

On the sell side, the largest reduction was Guardant Health, an estimated $42.1M trimmed.

  • Deep Track Capital's largest Q1 2025 buy was Sarepta Therapeutics: 899,731 shares worth $57.4M.
  • Deep Track Capital added most to Ionis Pharmaceuticals in Q1 2025, an estimated $86.1M increase.
  • Deep Track Capital's biggest Q1 2025 reduction was Guardant Health, cutting an estimated $42.1M.
  • Deep Track Capital fully exited SpringWorks Therapeutics in Q1 2025, selling an estimated $125M.
  • Deep Track Capital's ten largest holdings make up 53% of its $3.09B portfolio in Q1 2025.
  • Deep Track Capital opened 16 new positions and closed 10 in Q1 2025.
  • Deep Track Capital's portfolio value rose 15% quarter-over-quarter to $3.09B.

Based on Deep Track Capital's 13F filing for Q1 2025, filed 15 May 2025.